Half-year report · Q2

Period2024-10-01 → 2025-03-31
Filed2025-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥17.8bn2024-10-01 → 2025-03-31Cons.Net sales
Revenue¥32.2bn2023-10-01 → 2024-09-30Cons.Net sales (5-year summary)
Revenue¥16.6bn2023-10-01 → 2024-03-31Cons.Net sales
Operating income¥325m2024-10-01 → 2025-03-31Cons.Operating income
Operating income¥276m2023-10-01 → 2024-03-31Cons.Operating income
Ordinary income¥355m2024-10-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥408m2023-10-01 → 2024-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥302m2023-10-01 → 2024-03-31Cons.Ordinary income
Profit before tax¥400m2024-10-01 → 2025-03-31Cons.Income before income taxes
Profit before tax¥314m2023-10-01 → 2024-03-31Cons.Income before income taxes
Net income (owners)¥269m2024-10-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥237m2023-10-01 → 2024-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥211m2023-10-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income¥273m2024-10-01 → 2025-03-31Cons.Profit loss
Net income¥213m2023-10-01 → 2024-03-31Cons.Profit loss
Total assets¥18.5bnat 2025-03-31Cons.Assets
Total assets¥17.2bnat 2024-09-30Cons.Assets
Total assets¥19.8bnat 2024-03-31Cons.Total assets (5-year summary)
Total liabilities¥10.8bnat 2025-03-31Cons.Liabilities
Total liabilities¥9.7bnat 2024-09-30Cons.Liabilities
Net assets / equity¥7.7bnat 2025-03-31Cons.Net assets
Net assets / equity¥7.5bnat 2024-09-30Cons.Net assets
Net assets / equity¥7.6bnat 2024-03-31Cons.Net assets (5-year summary)
Cash and deposits¥1.5bnat 2025-03-31Cons.Cash and deposits
Cash and deposits¥764mat 2024-09-30Cons.Cash and deposits
Cash & equivalents¥1.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.2bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2023-09-30dCons.Cash and cash equivalents
Operating cash flow¥674m2024-10-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.0bn2023-10-01 → 2024-09-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥226m2023-10-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Investing cash flow¥62m2024-10-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥108m2023-10-01 → 2024-09-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥54m2023-10-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Financing cash flow¥6m2024-10-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥210m2023-10-01 → 2024-09-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥83m2023-10-01 → 2024-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥298.42024-10-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥263.542023-10-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥233.862023-10-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio40.9%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio43.0%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥7.2bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥7.2bn
—segment totalrevenue2024-10-01 → 2025-03-31¥17.8bn
—segment totalrevenue external2024-10-01 → 2025-03-31¥17.8bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥7.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥7.1bn
—segment totalrevenue2023-10-01 → 2024-03-31¥16.6bn
—segment totalrevenue external2023-10-01 → 2024-03-31¥16.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
Other clPrior1YearInstant125073000JPY
Other clCurrentQuarterInstant154100000JPY
Current liabilitiesPrior1YearInstant8711479000JPY
Current liabilitiesCurrentQuarterInstant9845335000JPY
Long term loans payablePrior1YearInstant38730000JPY
Long term loans payableCurrentQuarterInstant24390000JPY
Lease obligations nclPrior1YearInstant429619000JPY
Lease obligations nclCurrentQuarterInstant389526000JPY
Deferred tax liabilitiesPrior1YearInstant304843000JPY
Deferred tax liabilitiesCurrentQuarterInstant316689000JPY
Net defined benefit liabilityPrior1YearInstant67090000JPY
Net defined benefit liabilityCurrentQuarterInstant66372000JPY
Provision for directors retirement benefitsPrior1YearInstant118798000JPY
Provision for directors retirement benefitsCurrentQuarterInstant124433000JPY
Other nclPrior1YearInstant61343000JPY
Other nclCurrentQuarterInstant57247000JPY
Noncurrent liabilitiesPrior1YearInstant1020425000JPY
Noncurrent liabilitiesCurrentQuarterInstant978660000JPY
LiabilitiesPrior1YearInstant9731904000JPY
LiabilitiesCurrentQuarterInstant10823996000JPY
Capital stockPrior1YearInstant820400000JPY
Capital stockCurrentQuarterInstant820400000JPY
Capital surplusPrior1YearInstant881100000JPY
Capital surplusCurrentQuarterInstant881100000JPY
Retained earningsPrior1YearInstant5089637000JPY
Retained earningsCurrentQuarterInstant5262892000JPY
Treasury stockPrior1YearInstant-169040000JPY
Treasury stockCurrentQuarterInstant-169040000JPY
Shareholders equityPrior1YearInstant6622097000JPY
Shareholders equityCurrentQuarterInstant6795352000JPY
Valuation difference on available for sale securitiesPrior1YearInstant786144000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant755271000JPY
Remeasurements of defined benefit plansPrior1YearInstant10387000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant9313000JPY
Valuation and translation adjustmentsPrior1YearInstant796531000JPY
Valuation and translation adjustmentsCurrentQuarterInstant764584000JPY
Non controlling interestsPrior1YearInstant88942000JPY
Non controlling interestsCurrentQuarterInstant92812000JPY
Net assetsPrior1YearInstant7507572000JPY
Net assetsCurrentQuarterInstant7652750000JPY
Liabilities and net assetsPrior1YearInstant17239477000JPY
Liabilities and net assetsCurrentQuarterInstant18476746000JPY
Net salesPrior1YTDDuration16617840000JPY
Net salesCurrentYTDDuration17806883000JPY
Cost of salesPrior1YTDDuration14947234000JPY
Cost of salesCurrentYTDDuration16127489000JPY
Gross profitPrior1YTDDuration1670606000JPY
Gross profitCurrentYTDDuration1679394000JPY
Selling general and administrative expensesPrior1YTDDuration1394567000JPY
Selling general and administrative expensesCurrentYTDDuration1354357000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-09-30pass rounding
balance sheet identityconsolidated 2025-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-10-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-10-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-10-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-10-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-10-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass